Public Profile

Neuropathix, Inc.

Neuropathix, Inc., headquartered in the United States, is a pioneering company in the biotechnology industry, specialising in innovative solutions for neurological disorders. Founded in 2018, Neuropathix has quickly established itself as a leader in the development of advanced therapeutics aimed at addressing unmet medical needs in the field of neurology. The company’s core offerings include cutting-edge drug formulations and delivery systems designed to enhance patient outcomes. Neuropathix is recognised for its unique approach to neuropharmacology, leveraging proprietary technologies that set it apart from competitors. With a strong focus on research and development, Neuropathix has achieved significant milestones, positioning itself as a key player in the market for neurological treatments.

DitchCarbon Score

How does Neuropathix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Neuropathix, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Neuropathix, Inc.'s reported carbon emissions

Neuropathix, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is unclear how the company is addressing its carbon footprint or what commitments it has made towards climate action. In the absence of concrete data, it is essential for Neuropathix to establish clear climate commitments and reduction initiatives to align with industry standards and contribute to global sustainability efforts.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Neuropathix, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Neuropathix, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Neuropathix, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Endexx Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Elixinol Wellness Limited

AU
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Curaleaf Holdings, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Charlotte's Web Holdings, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Zynerba Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Ovation Science Inc.

CA
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers